Skip to main content
SpringerLink
Log in

Alzheimer's therapy: a BACE in the hand?

  • Community Corner
  • Published:

From Nature Medicine

View current issue Submit your manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Atwal, J.K. et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Trans. Med. 3, 84ra43 (2011)

    Article  Google Scholar 

  2. Yu, Y.J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Trans. Med. 3, 84ra44 (2011)

    Article  Google Scholar 

  3. Yamakawa, H. et al. β-secretase inhibitor potency is decreased by aberrant beta-cleavage location of the “Swedish mutant” amyloid precursor protein. J. Biol. Chem. 285, 1634–1642 (2010).

    Article  CAS  Google Scholar 

  4. DeMattos, R.B. et al. Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).

    Article  CAS  Google Scholar 

  5. Vassar, R. et al. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).

    Article  CAS  Google Scholar 

  6. De Strooper, B., Vassar, R. & Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99–107 (2010).

    Article  CAS  Google Scholar 

  7. Eli, Lilly . Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase 3 clinical trials. <http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794> (2010).

  8. Rinne, J.O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).

    Article  CAS  Google Scholar 

  9. Alzheimer Research Forum. Uppsala: Is tau immunotherapy taking off? <http://www.alzforum.org/new/detail.asp?id=2824> (2011).

  10. Kim, S.H. et al. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloidβ42 from isolated intact nerve terminals. J. Neurosci. 30, 3870–3875 (2010).

    Article  CAS  Google Scholar 

  11. Yoshimizu, T. & Chaki, S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 315, 493–496 (2004).

    Article  CAS  Google Scholar 

Download references

Ethics declarations

Competing interests

S.G. is a grantee from Amicus Pharmaceuticals and a data and safety monitoring board member of Pfizer/Johnson&Johnson Alzheimer Immunotherapy Alliance.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alzheimer's therapy: a BACE in the hand?. Nat Med 17, 932–933 (2011). https://doi.org/10.1038/nm0811-932

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0811-932

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation